FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases “The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives ...
The US Food and Drug Administration (FDA) has granted approval for Revvity’s Auto-Pure 2400 liquid handling platform, used in conjunction with the T-SPOT.TB test. This approval introduces an ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, ...
Flowchart of all participants. TB: tuberculosis; T-SPOT.TB: interferon-gamma release assay; TST: tuberculin skin test; C-TST: creation tuberculin skin test; PTB: pulmonary tuberculosis; EPTB: ...
(RTTNews) - Revvity, Inc. (RVTY), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. tuberculosis (TB) test. "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results